HIGHLIGHTS
- who: UC Irvine and collaborators from the University of have published the research work: UC Irvine, in the Journal: (JOURNAL) of December/12,/2012
- what: The study was sponsored by the National Cancer Institute, which provided bevacizumab without charge. The Trial Outcome Index of the Functional Assessment of Cancer Therapy (FACT)-Cervix (FACT-Cx-TOI) survey was used to assess physical and functional well-being (on a scale from 0 to 4, with higher scores indicating worsening well-being). Ninety-seven percent of patients discontinued the study treatment; the most common reason was disease progression . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.